Previous Page  25 / 40 Next Page
Information
Show Menu
Previous Page 25 / 40 Next Page
Page Background

PARP inhibitors as maintenance in ovarian cancer relapse

Agenda

Biomarkers and development of PARPi in ovarian cancer

Overview of efficacy outcomes by biomarkers cohorts

Long-term benefit

Safety profile and quality of life

Future of PARP inhibitors as maintenance in recurrence setting